Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 387Breast Neoplasms 368Colorectal Neoplasms 242Stomach Neoplasms 220Carcinoma, Hepatocellular 155Lung Neoplasms 125Neoplasms 122Pancreatic Neoplasms 113Prostatic Neoplasms 101Rectal Neoplasms 98Neoplasm Metastasis 98Recurrence 92Ovarian Neoplasms 92Nasopharyngeal Carcinoma 89Esophageal Neoplasms 84Esophageal Squamous Cell Carcinoma 83Lymphoma, Large B-Cell, Diffuse 79Melanoma 78Lymphoma 72Small Cell Lung Carcinoma 71Leukemia, Myeloid, Acute 71Uterine Cervical Neoplasms 70Brain Neoplasms 70Sarcoma 69Squamous Cell Carcinoma of Head and Neck 67Multiple Myeloma 67Head and Neck Neoplasms 67Carcinoma, Renal Cell 65Triple Negative Breast Neoplasms 63Colonic Neoplasms 55

Interventions

atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Unknown × Safety Issues × Clear all
NCT03620435 2018-08-13

Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer

McGill University Health Centre/Research Institute of the McGill University Health Centre

Phase 2 Unknown
25 enrolled

Safety Issues

Data powered by HemOnc (CC BY 4.0) Colophon âš¡